Cassia Capital Partners’s Pfizer PFE Stock Holding History

Cassia Capital Partners’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-16,315	Closed	-$472K	–	65
2024 Q3	$472K	Sell	16,315 -818	-5%	-$23.9K	0.31%	49
2024 Q2	$479K	Sell	17,133 -4,609	-21%	-$127K	0.32%	48
2024 Q1	$603K	Buy	21,742 +7,612	+54%	+$211K	0.4%	47
2023 Q4	$407K	Sell	14,130 -340	-2%	-$10.3K	0.34%	51
2023 Q3	$480K	Buy	14,470 +341	+2%	+$12.1K	0.39%	32
2023 Q2	$518K	Buy	+14,129	New	+$550K	0.41%	25
2022 Q4	–	Sell	-6,841	Closed	-$299K	–	82
2022 Q3	$299K	Sell	6,841 -225	-3%	-$10.9K	0.27%	31
2022 Q2	$370K	Buy	7,066 +10	+0.1%	+$510	0.37%	24
2022 Q1	$365K	Buy	7,056 +128	+2%	+$6.64K	0.29%	29
2021 Q4	$409K	Buy	+6,928	New	+$343K	0.27%	23
2021 Q3	–	Sell	-5,235	Closed	-$205K	–	125
2021 Q2	$205K	Buy	+5,235	New	+$204K	0.15%	46

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cassia Capital Partners's PFE Position: Q4 2024 in Review

Cassia Capital Partners sold out of Pfizer (PFE) in Q4 2024, closing a stake of 16,315 shares — an estimated $472K sold.

Cassia Capital Partners first reported a position in PFE in Q2 2021 and held it in 11 quarters. The position peaked at $603K in Q1 2024. 2,996 funds tracked by Wall St. Rank hold PFE as of Q4 2024.

Cassia Capital Partners reported no remaining Pfizer position as of Q4 2024 after selling out during the quarter.
Cassia Capital Partners sold 16,315 Pfizer shares in Q4 2024, an estimated $472K.
Cassia Capital Partners first reported a position in Pfizer in Q2 2021 and held it in 11 quarters.
Cassia Capital Partners's Pfizer position peaked at $603K in Q1 2024.
2,996 funds tracked by Wall St. Rank held Pfizer as of Q4 2024.

Based on Cassia Capital Partners's 13F filing for Q4 2024, filed 27 Jan 2025.